Dr. Keating joined the Faculty at Penn in 2012, and has his primary appointment in the Division of Transplantation in the Department of Surgery. His major research interests focus on the analyses of miRNA, mRNA and polymorphisms of donor and recipients genomes, with the aim of delivering individualized treatment of immunosuppression therapies post-transplant, and prediction of genetic signals that may underpin graft rejection and complications of rejection. Dr. Keating is Principal Investigator of genome-wide association studies (GWAS) for solid-organ transplant cohorts within the Children's Hospital of Philadelphia, and of a number of urinary omic studies. He instigated the formation of an international genomics consortium (iGeneTRAIN) for large-scale genomic studies using > 50,000 DNA samples from a number of international transplant studies (www.igenetrain.org). Dr. Keating is also a member of the Pharmacogenomics and Return of Results working groups of the NHGRI electronic medical record and genomics (eMERGE) network which is integrating clinical genetic data into patient's electronic medical records for clinical decision support for individualize dosing of patients. Dr. Keating has led or co-authored over 120 genomic publications and has given over 100 presentations in 25 countries including numerous national and international conferences. Dr. Keating is also PI of a prospective NIH-funded study looking at post-transplant outcomes in 12 North American pediatric renal transplant centers.